The Weinberg Group

What The Weinberg Group does

The Weinberg Group is a global regulatory and compliance services firm serving pharmaceutical, biotechnology, and medical device organizations across the full product lifecycle. The company operates an integrated portfolio spanning seven core service areas: Regulatory Sciences (covering FDA, EMA, and other national competent authorities for drugs, biologics, medical devices, and diagnostics across pre- and post-approval), CRO Services (multi-phase clinical development and decentralized trial support), Quality & Compliance (GxP auditing, computer system validation, inspection readiness), Pharmacovigilance (clinical and post-marketing safety, QPPV/LPPV, case and signal management), Medical Information (24/7/365 global contact centers, adverse event and complaint intake, patient support), FSP Solutions (embedded functional service provider teams across clinical operations, biostatistics, data sciences, and medical writing), and Digital Transformation (digital blueprint, data strategy, technology services, and validation). AI and ML are deployed within quality compliance and medical information workflows, including a generative AI capability for medical information delivery recognized by ECCCSA in 2025.

The business model is professional services, monetized through bespoke partnership engagements and FSP embedded-team contracts with enterprise life sciences clients. Pricing is not publicly disclosed and is structured around customized scopes rather than standardized SKUs. The go-to-market motion is direct enterprise field sales, executed through dedicated program managers and asset strategists who operate as extensions of client internal teams. Customer segmentation is horizontal across pharma, biotech, and medical device categories, with additional verticalization via therapeutic-area service lines (including cell and gene therapy) and a Digital Transformation practice that bridges life sciences and technology. The firm maintains SOC 1 and SOC 2 Type 2 compliance, has validated SBTi-approved net-zero targets, and operates a global footprint with offices referenced in the UK (HQ) and Sweden.

Data limitations are notable: there is no disclosed revenue, no customer logos or concentration data, and the firmographic record lists 101–250 employees against a 1983 founding date for The Weinberg Group (Washington, US), while related entity ProPharma Group MIS Limited is registered in England and Wales (company number 03671574) with a 1999 founding date and overlapping service descriptions. The firm's evolution into a global multi-service life sciences platform is supported by recent leadership additions (CCO in May 2026, VP HEOR and Market Access in June 2026) and recognition across regulatory, clinical trials, and AI excellence programs.

Name

The Weinberg Group

Legal name

ProPharma Group MIS Limited

Website

https://weinberggroup.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

The Weinberg Group is a global regulatory and compliance services firm serving pharmaceutical, biotechnology, and medical device organizations across the full product lifecycle, spanning regulatory consulting, CRO, quality compliance, pharmacovigilance, FSP, and digital transformation services with AI-augmented medical information and quality workflows.

Ownership category

akta.pro rank

Product category

Life Sciences Regulatory and Compliance Consulting

NAICS

Scientific Research and Development Services (5417), Management Consulting Services (54161)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL), Pharmacovigilance Quality & Compliance (PV audits, QPPV support, PSMF) (HLAGAKAH), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Quality Assurance, GxP Compliance & Auditing FSP (HLAGAOAE), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Regulatory consulting
• Life sciences compliance
• Clinical research services
• Pharmacovigilance services
• Medical information services

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Regulatory Sciences Consulting: Comprehensive regulatory consulting services including FDA regulatory consulting, European regulatory development, marketing authorization holder partnerships, regulatory operations, and global medical writing. Supports pre- and post-approval regulatory submissions for drugs, biologics, medical devices, and diagnostics.
2. CRO Services: Full-service contract research organization services including site and patient services, biostatistics and programming, and medical device clinical support for multi-phase clinical development.
3. Quality & Compliance Services: GxP compliance and auditing, computer system validation, inspection readiness, clinical quality assurance, and commissioning qualification validation services.
4. Pharmacovigilance Solutions: Clinical and post-marketing pharmacovigilance services including safety systems, QPPV/LPPV support, case management, signal management, and global ICSR submissions.
5. Medical Information Services: Global contact center support, adverse event intake, product complaint handling, patient support services, and medical communications with 24/7/365 availability.
6. FSP Solutions: Functional service provider solutions as an extension of client internal teams, including clinical operations, data sciences, biostatistics, medical writing, and decentralized clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

The Weinberg Group delivers regulatory and compliance consulting services to pharmaceutical, biotechnology, and medical device companies across the entire product lifecycle. Through its affiliated ProPharma organization, it provides a full suite including Regulatory Sciences, CRO (Contract Research Organization) Services, Quality & Compliance, Pharmacovigilance, Medical Information, Functional Service Provider (FSP) Solutions, and Digital Transformation Services. These offerings support clients with submissions, clinical development, quality systems, safety surveillance, scientific communications, and technology-enabled transformation initiatives.

Product overview

ProPharma is a comprehensive life sciences consulting organization offering an end-to-end suite of bespoke services across the full product lifecycle. The core portfolio includes seven major service areas: Regulatory Sciences (FDA, EMA, and global regulatory support), CRO Services (clinical development and study execution), Quality & Compliance (GxP compliance and validation), Pharmacovigilance Solutions (safety monitoring from clinical through post-approval), Medical Information (24/7 contact centers and medical communications), FSP Solutions (functional service provider model for clinical operations), and Digital Transformation (technology enablement for life sciences). The company also operates across multiple therapeutic areas including Oncology, Cardiovascular, CNS, Infectious Disease/Vaccines, Cell and Gene Therapy, Ophthalmology, Pediatrics, Rare Disease, Respiratory, and Obesity & Diabetes. Services are designed to be customizable and partnership-driven, enabling clients to navigate regulatory, clinical, and compliance challenges throughout drug, biologic, medical device, and diagnostic development.

Differentiator

Problem solved

Functional benefit

Products and services

• Regulatory Sciences

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Real Chemistry: Healthcare and life sciences consulting firm offering medical affairs, regulatory, and commercial services. Comparable in size and scope, particularly in medical communications and HEOR capabilities.
• Worldwide Clinical Trials: Mid-sized global CRO offering clinical trial, biostatistics, and regulatory services to pharma and biotech. Comparable in scale, service breadth, and customer mix to the company.
• Medpace: Mid-sized full-service CRO focused on small and mid-sized biopharma, with strong therapeutic expertise. Closely comparable business model and customer profile, though with a heavier clinical trial focus.

Broad incumbents

• Parexel International: Large global CRO with deep regulatory, clinical, and market access capabilities, particularly strong in regulatory consulting and biopharmaceutical services. Direct competitor in the same enterprise customer segment.
• Syneos Health: Large biopharmaceutical services organization combining CRO and contract commercial services. Competes across clinical, regulatory, and FSP engagements with global scale.
• ICON plc: Major global CRO providing clinical research, consulting, and FSP services to pharma and biotech. Directly comparable in CRO and FSP offerings, with broader scale and a more extensive therapeutic area footprint.
• IQVIA: The largest global CRO and life sciences services provider, offering clinical research, regulatory, and technology services. Competes with the company across CRO, regulatory consulting, and FSP engagements, but at significantly greater scale.
• Labcorp Drug Development (Fortrea): Spin-off of Labcorp's CRO business, offering full-service clinical development and central laboratory services. Competes across CRO and FSP engagements with global delivery capability.
• Charles River Laboratories: Major CRO with strengths in preclinical, discovery, and clinical development services. Adjacent competitor in early-phase and cell/gene therapy support.

Emerging players

• Veeva Systems: Life sciences cloud platform provider with strong regulatory and quality management software offerings. Adjacent competitor, particularly in the Digital Transformation and regulatory operations segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/propharmagroup
• Xx.com/weinberggroup

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Weinberg Group